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Efforts in experimental therapeutics of atherosclerosis are mostly focused on identifying candidate tar-
gets that can be exploited in developing new strategies to reduce plaque progression, induce its re-
gression and/or improve stability of advanced lesions. Plaque macrophages are central players in all these
processes, and consequently a signiﬁcant amount of research is devoted to understanding mechanisms
that regulate, for instance, macrophage apoptosis, necrosis or migration. Macrophage diversity is a key
feature of the macrophage population in the plaque and can impact many aspects of lesion development.
Thus, searching for molecular entities that contribute to atherorelevant functions of a speciﬁc macro-
phage type but not others may lead to identiﬁcation of targets that can be exploited in phenotype se-
lective modulation of the lesional macrophage. This however, remains an unmet goal. In recent years
several studies have revealed critical functions of micro-RNAs (miRs) in mechanisms of macrophage
polarization, and a number of miRs have emerged as being speciﬁc of distinctive macrophage subsets.
Not only can these miRs represent the ﬁrst step towards recognition of phenotype speciﬁc targets, but
they may also pave the way to reveal novel atherorelevant pathways within macrophage subsets. This
article discusses some of these recent ﬁndings, speculates on their potential relevance to atherosclerosis
and elaborates on the prospective use of miRs to affect the function of plaque macrophages in a phe-
notype selective manner.
& 2015 The Author. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND
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Atherosclerosis, the major cause of coronary artery disease, is a
chronic arterial disease dominated by a maladaptive inﬂammatory
response [1,2]. Clinical manifestations of atherosclerosis, which.V. This is an open access article u
C Mail stop 1008, Toledo, OHdirectly relate to the molecular and cellular features of the plaque,
go from ischemic symptoms due to lesions causing critical arterial
stenosis, to acute thromboembolic events that follow plaque
rupture [3,4]. The development of atherosclerotic lesions implies a
complex intermingling among endothelial and smooth muscle
cells, macrophages, and cytokines and inﬂammatory mediators
that lodge in the lesion setting. From a therapeutic perspective,
desirable goals in atherosclerosis include reducing plaque pro-
gression, improving stability of advanced lesions and/or inducingnder the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
G. Vazquez / Biochemistry and Biophysics Reports 3 (2015) 202–206 203plaque regression. Plaque macrophages are major protagonists in
all these processes. For instance, the balance between accumula-
tion of apoptotic macrophages and their clearance from the lesion
through efferocytosis modulates cellularity of early lesions and
necrosis and stability of advanced plaques [5,6], and macrophage
egress from the lesion is a major determinant of plaque regression
[7,8]. Despite the progress made in identifying mechanisms asso-
ciated to these processes, the potential applicability to human
pathology of strategies aimed at manipulating macrophage apop-
tosis and/or migration is still a matter of debate. An often ignored
aspect is the fact that the macrophage population that inhabits in
the atherosclerotic lesion is composed of phenotypically and
functionally distinct subsets. Although in recent years this concept
has to some extent re-gained attention in the ﬁeld, experimental
work examining distinct effects of individual macrophage subsets
in plaque composition, progression and stability appears spor-
adically in the literature and with little or no therapeutic per-
spective [9,10]. Acknowledging the distinctive impact of macro-
phage diversity on plaque characteristics is of most importance, as
it may lead to some deﬁnitions to develop alternative therapeutic
strategies. The identiﬁcation of molecular entities that speciﬁcally
contribute to atherorelevant functions of a particular macrophage
type but not others remains an as yet unmet goal. Filling this gap
of knowledge may drive drug development toward targets to
modulate detrimental phenotype selective functions while mini-
mally interfering with those of the desirable types.
Evidence accumulated in recent years revealed key roles of
micro-RNAs (miRs) in macrophage functions that are of relevance
to atherosclerosis, in particular in the regulation of components of
the reverse cholesterol transport system (RCT) [11,12]. Also, a
number of recent reports, although not aimed at studying ather-
osclerosis, underscored critical functions of miRs in mechanisms of
macrophage polarization (see Section 3 below). This is of upmost
importance, as phenotype selective miRs may lead the way to-
wards identiﬁcation of phenotype speciﬁc targets, or to becoming
target candidates themselves. Here I discuss some recent salient
ﬁndings regarding miRs and macrophage diversity, and speculate
on their potential relevance to atherosclerosis and the prospective
use of these miRs to manipulate plaque macrophage functions in a
phenotype selective manner.2. Macrophage diversity in atherosclerosis
The presence of distinctive macrophage subsets in athero-
sclerotic lesions of humans and animal models of the disease is
well documented [13–15]. In brief, the M1 or inﬂammatory, or
classically activated, and the M2 or anti-inﬂammatory, or alter-
natively activated types, dominate in atherosclerosis [9,10,16].
In vitro, naïve macrophages can be induced to differentiate to the
M1 type with interferon γ (IFNγ) and/or lipopolysaccharide (LPS),
whereas interleukins 4 or 13 (IL4, IL13) promote M2 differentiation
[15,17]. Macrophages grown in granulocyte-macrophage colony
stimulating factor-1 (GM-CSF1) or in macrophage colony stimu-
lating factor-1 (M-CSF1) are sometimes regarded as, respectively,
M1 or M2, but there is insufﬁcient evidence to link these pheno-
types to GM-CSF1- or M-CSF1-derived cells (see also [18]). Unlike
the more controlled in vitro setting however, assigning phenotypes
to plaque macrophages, which are exposed to a myriad of stimuli
of varying proportions, is not trivial. Indeed, evidence for fully
divergent phenotypes in atherosclerotic plaques is still lacking.
The study of the transcriptome of plaque macrophages has ad-
vanced enormously with the use of highly sensitive protocols for
quantitative real-time polymerase chain reaction (qRT-PCR) that
can be applied to macrophages isolated from lesions by laser
capture microdissection (LCM) [19,20]. As this approach spreads,we should expect better comparisons between the marker sig-
nature of in vitro M1 and M2 macrophages and that of LCM cap-
tured lesional cells. This can also provide a robust proﬁling of
macrophage markers somewhat reﬂective of the perturbations
these cells encountered in vivo, something difﬁcult, if not im-
possible to recapitulate in vitro.
During atherosclerosis the relative abundance of M1 and M2
macrophages (M1/M2 ratio) varies with lesion stage and in general
increases as the lesion progresses. But these types co-exist
throughout plaque development, intermediate phenotypes exist
and phenotype inter-conversion can occur [15,16]. The M2 mac-
rophages play a key role in regression of atherosclerosis. Indeed,
plaque regression is often accompanied by a decrease in M1/M2
ratios [21,22]. Augmented macrophage egress from advanced
plaques with concomitant enrichment in M2 cells was found to
correlate with plaque regression in atherosclerotic mice subjected
to lipid lowering interventions [21]. Notably, endoplasmic re-
ticulum (ER) stress, a major pro-apoptotic mechanism in lesional
macrophages [23,24], is required for differentiation of M2 macro-
phages, to the extent that suppression of ER stress shifts M2's
towards the M1 phenotype [25]. Intuitively, this suggests that in-
terventions targeting components of the unfolded protein re-
sponse (UPR) as a strategy to reduce macrophage apoptosis but
with no discrimination of phenotypes, may favor M2-to-M1 con-
version, with a subsequent negative effect on plaque character-
istics. Hence, manipulation of macrophage apoptosis and/or egress
from plaques in a phenotype selective manner may be an attrac-
tive approach to improve stability and/or favor regression of es-
tablished lesions. Molecular elements that contribute to these
processes in a subset selective fashion have not been system-
atically investigated. Recent work from our group shows that in
M1, but not M2 macrophages, genetic or pharmacological inhibi-
tion of the calcium-permeable cation channel Transient Receptor
Potential Canonical 3 (TRPC3) impairs activation of the UPR and
reduces ER stress-induced apoptosis, despite this channel being
expressed and functional in both macrophage subsets [26,27].
Although awaiting in vivo validation, these ﬁndings reveal TRPC3
as a molecular element whose function selectively affects a spe-
ciﬁc macrophage type, and suggest that targeting TRPC3, rather
than its downstream effectors, may be a way to modulate mac-
rophages in a phenotype selective manner. This brings about an
important new concept, i.e., modulating macrophage functions in a
phenotype selective way, rather than targeting macrophages in a
phenotype selective manner. The latter implies the targeting of
molecules uniquely expressed in, for instance, M1 cells but not in
the M2's. This is currently unattainable as most signaling mole-
cules and phenotypic markers are to some extent expressed in all
macrophage types. In contrary, affecting macrophage functions in
a phenotype selective manner refers to the recognition of mole-
cules that, as seems to be the case for the pro-apoptotic role of
TRPC3 in M1 macrophages, serve to a speciﬁc function in one
macrophage type but not in the other, regardless of such mole-
cules being expressed in both subsets.
TRPC3 is ubiquitously expressed [28] and this may, a priori, be
envisaged as a limitation for selective targeting. In fact, this is a
concern with most signaling molecules so far identiﬁed in mac-
rophages as of potential therapeutic use in atherosclerosis. Im-
portantly, macrophage-targeted drug delivery is now possible
through nanoparticle delivery systems [29,30], and this has been
shown to represent a viable approach to target plaque macro-
phages [31].
3. Micro-RNAs, macrophage diversity and atherosclerosis
Micro-RNAs (miRs) are a large family of small (22 nucleo-
tides) non-coding RNA molecules that regulate gene expression
G. Vazquez / Biochemistry and Biophysics Reports 3 (2015) 202–206204post-transcriptionally by binding to the 3'-untranslated region
(3'UTR) of target mRNAs and repress their expression [32].
There is compelling evidence supporting critical roles of miRs
in regulation of RCT [11,12,33,34]. An important discovery was the
demonstration that short-term antagonism of miR-33, a potent
repressor of ATP-binding cassette transporter-1 (ABCA1) in mice
with established atherosclerosis promotes plaque regression and
improves plaque stability [35]. More recently however, studies of
long-term inhibition of miR-33 in non-atherosclerotic mice
showed deleterious effects such as mild hepatic steatosis and hy-
pertriglyceridemia, raising concerns on the therapeutic potential
of miR-33 in atherosclerosis [36]. Despite this, the studies on miR-
33 in mouse models of atherosclerosis demonstrated that ma-
nipulation of miRs in plaque macrophages is feasible and provided
proof of principle on the potential therapeutic use of anti-miRs in
atherosclerosis. Unlike the well-recognized impact of miRs on RCT,
their effects on mechanisms of macrophage polarization are just
beginning to be appreciated. Studies using microarray analysis to
examine expression proﬁles of miRs in bone marrow-derived
macrophages from Balb/c mice showed that miR-181a, miR-155-
5p, miR-204-5p, miR-451 and miR-127-3p were increased in M1
macrophages – induced with LPS plus IFNγ – compared to M2's –
induced with IL4 [37]. In contrary, the expression of miR-125b-5p,
miR-146a-3p, miR-143-3p and miR-145-5p was higher in M2
compared to the M1 macrophages [37]. This was conﬁrmed by
qRT-PCR, and analysis of their potential biological relevance by
functional categorization showed association of miR-181a, miR-
155-5p, miR-204-5p, and miR-146a-3p with apoptosis. Potential
targets for these miRs were however not explored, and thus it
remains to be determined whether upregulation of any of these
miRs truly affects apoptosis of M1 or M2 cells.
Studies in bone marrow-derived macrophages from C57BL/6
mice grown in GM-CSF1 or M-CSF1, revealed interesting aspects of
the biological relevance of miR-125a-5p in M2 macrophages [38].
In these cells stimulation of Toll-like receptors (TLR) 2 and 4, but
not TLR3, favored expression of miR-125a-5p. Of importance, miR-
125b-5p, which has the same seed sequence as miR-125a-5p, was
downregulated by TLR4 stimulation [38], probably illustrating the
fact that sequence context outside the seed region also affects the
binding of miRs to their targets and their expression [39]. Notably,
in macrophages overexpressing miR-125a-5p, LPS treatment fa-
vored M2 differentiation, whereas knockdown of miR-125a-5p
promoted M1 differentiation [38]. TLR2 and TLR4 are key in me-
chanisms of ER stress-induced apoptosis in macrophages [40].
Hence, it is possible that upregulation of miR-125a-5p under
conditions of ER stress contributes to modulation of downstream
apoptotic pathways. Considering the strong effect of miR-125a-5p
in suppressing the M1 phenotype while favoring M2 activation,
and the permissive effect of ER stress on differentiation of M2
macrophages, the question raises whether miR-125a-5p mod-
ulates mechanisms that drive the M2 phenotype when macro-
phages undergo ER stress. In vivo studies examining the impact of
miR-125a-5p mimics on plaque necrosis and regression and how
these correlate with M1/M2 ratios may bring answers to this
question. Findings on the expression of miR-125a-5p in polarized
human macrophages contrast with those in mice. Eigsti et al. [41]
found that miR-125a-5p was downregulated by both interferons
(M1 inducers) and IL4 (M2 inducer) during the transition mono-
cyte-to-macrophage. Accumulation of miR-146a and miR-155 was
increased by TLR activation whereas that of miR-193b and miR-
222 was induced by IL4 [41]. Although species differences – mouse
in [38] vs. human in [41] – may account for differential expression
of a particular miR, these ﬁndings also suggest that the miR sig-
nature of monocytes is ﬁnely tuned during differentiation to
macrophages and strongly inﬂuenced by environmental cues.
It has been found that early lesions in Apoe knockout mice havehigh levels of the macrophage-derived miR-342-5p and miR-155
[42]. MiR-342-5p targets the 3'UTR of Akt1, leading to augmented
production of inﬂammatory mediators by macrophages through a
mechanisms that also involves upregulation of miR-155. This
correlated with lesion progression, and local or systemic admin-
istration of an antagomir against miR-342-5p reduced plaque
growth [42]. The phosphatidylinositol-3-kinase (PI3K)/AKT axis is
key to macrophage survival [43,44] and also seems required for
proper migration signaling downstream the chemokine receptor
CCR7 [45]. Hence, the beneﬁcial impact of miR-342-5p antagonism
in early lesions may to some extent be related to increased mac-
rophage survival and enhanced migration of surviving cells. Plaque
size reduction in the face of increased macrophage survival seems
difﬁcult to reconcile with the idea that reduced macrophage
apoptosis in early plaques leads to increased cellularity [6,46].
However, we and others [17,26] have shown that in early lesions of
Apoe knockout mice M1 macrophages make up for a small portion
of the total macrophage population. Therefore, it is conceivable
that in early stages the beneﬁt of higher migration capacity of
macrophages with reduced expression of miR-342-5p prevails
over any detrimental effect due to increased survival. Three stu-
dies reported upregulation of miR-155 in M1 macrophages
[37,41,42]. Interestingly, miR-155 was found to be upregulated in
aortic plaques of Apoe knockout mice fed a high fat diet and in
carotid plaques of Apoe knockout mice with partial carotid artery
ligation [47]. In the latter model, hematopoietic deﬁciency of miR-
155 results in reduced plaque burden and cellularity [47]. This is in
part due to loss of miR-155-mediated repression of B-cell leuke-
mia/lymphoma 6 (BCL6), a transcription factor that attenuates
Nuclear Factor kappa B pro-inﬂammatory signaling [47]. The role
of miR-155 in atherosclerosis was further investigated in recent
studies from the same laboratory. Using Apoe knockout mice fed
an atherogenic diet for twelve and twenty four weeks to induce,
respectively, development of early and advanced lesions, Wei et al.
[48] examined the impact of global- and hematopoietic-deﬁciency
of miR-155 on the characteristics of atherosclerotic lesions. Lack of
miR-155 resulted in early plaques of bigger size and cellularity
compared to control animals [48]. Notably, CSF1-dependent mac-
rophage proliferation in vitro was markedly reduced by miR-155,
suggesting that the increased in lesion volume and cellularity in
the miR-155 knockout mice was related to the impact of this miR
on macrophage proliferation. Contrarily, advanced plaques of Apoe
knockout mice beneﬁted from miR-155 deﬁciency, as manifested
by a reduction in both apoptotic cell number and areas of necrosis
[48]. This is part explained by an inhibitory action of miR-155 on
BCL6-dependent regulation of efferocytosis, which is critical in
preventing necrotic core growth in advanced plaques [6,49]. Al-
together, these studies illustrate opposite roles of macrophage
miR-155 in early vs. advanced atherosclerosis, highlighting the
importance of longitudinal in vivo studies to better deﬁne the
impact of a particular miR in macrophage functions in the plaque.
There are discordant ﬁndings on the effects of miR-21 in
macrophage polarization. Caescu et al. [50] showed that treatment
of macrophages with CSF1 upregulates miR-21 resulting in a ro-
bust anti-inﬂammatory effect which favors M2 differentiation [50].
This is in agreement with the concept of CSF1 receptor signaling
being essential for M2 differentiation and inhibition of the M1
phenotype [51]. Wang et al. [52] found that in thioglycollate-eli-
cited peritoneal macrophages miR-21 is downregulated by acti-
vation of a prostaglandin E2 (PGE2)/cyclic AMP pathway which
results in enhanced expression of M2- but not M1-related genes.
Accordingly, peritoneal macrophages from miR-21 deﬁcient mice
were predominantly of the M2 type [52]. A potential explanation
for the discordant ﬁndings from these two studies is that a dif-
ferent baseline repertoire of miRs in these distinct macrophage
populations – cell lines [53] vs. elicited peritoneal macrophages
Table 1
This table summarizes some of the most salient recent ﬁndings regarding differential expression of miRs in the M1 and/or M2 macrophage subtypes (see text for discussion).
In most instances, the impact of such differential expression in atherosclerosis has not been evaluated (indicated as “n.d.”); this author's speculations on potential roles in
atherogenesis are indicated and followed by a question mark. When speciﬁed in the original publication, the phenotype inducing agent is indicated in parenthesis.
miR Species Macrophage type Effect on atherosclerosis Reference
181a, 155-5p, 204-5p, 451,
127-3p
Mouse M1(LPS, IFNg)4M2(IL4) n.d. [37]
125b-5p, 46a-3p, 143-3p,
145-5p
Mouse M2(IL4)4M1(LPS, IFNg) n.d. [37]
125a-5p Mouse M2(GM-CSF1/M-CSF1) Promotion of M2 phenotype under ER stress? [38]
146a, 155 Human M1(LPS)4M2(IL4) n.d. [41]
193b, 222 Human M2(IL4)4M1(LPS) n.d. [41]
155 Mouse M14M2 Promotes NFkB signaling; differential effect on plaque size and cellularity
(early vs. advanced plaques)
[37],[41],[42],[47],[48]
21 Mouse M2(CSF1)4M1 Plaque regression? [48]
21 Mouse M14M2 (elicited peritoneal) n.d. [50]
223 Mouse M2(IL4)4M1 n.d. [53]
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tially affect regulation of miR-21 expression. The ﬁndings dis-
cussed in this section are summarized in Table 1.4. Novel targeting venues at the expense of added complexity:
quo vadis?
Examination of the transcriptome of plaque macrophages by
combining LCM with microarray or RNA-seq analysis, has gener-
ated valuable information on the expression signature of miRs and
how these compare to the markers proﬁle of in vitro generated M1
and M2 macrophages. Notably, some information on the tran-
scriptome of plaque macrophages has found good correlation with
what one would expect from in vitro M1 and M2 cells [21,35,54].
Comparative microarray and RNA-seq transcriptome analysis like
those performed in some of the studies above, renders a high
number of miRs whose expression is changed under speciﬁc ex-
perimental conditions. Validation of these changes by qRT-PCR
narrows the number of candidates for further functional valida-
tion. However, most miRs have hundreds, if not thousand potential
targets, and a combination of technical, time and cost limitations
often leads to selection, with not little bias, of a few targets for
further investigation. This approach can impose, a priori, sig-
niﬁcant risks with in vivo validation of miR mimics –agomirs – or
antagonists –antagomirs. Whereas a particular miR may have a
strong repressing effect on, for instance, a target whose expression
is desirable in the lesion setting –v.g., macrophage CCR7-, antag-
onizing this miR to promote advantageous pathways may con-
comitantly lead to upregulation of non-desirable genes. This calls
for a rationale selection of targetable miRs. In this regard, it is vital
to gather minimal knowledge of functional categories of additional
targets whose de-repression – when antagomirs are used – or
downregulation – when agomirs are used – might negatively
impact the outcome of the targeting strategy. An extra level of
complexity is added by the discovery that macrophage-derived
microvesicles, or exosomes, contain functional miRs that can be
delivered to target cells, including other macrophages and
monocytes [55–57]. In this scenario, dominating miRs in a parti-
cular macrophage subset could be delivered to newly recruited
monocytes or to neighbor macrophages to “instigate” speciﬁc
cellular responses or to induce differentiation into a particular
phenotype. For example, miR-223, which is speciﬁc of IL4-induced
M2 macrophages, has been shown to be microvesicle-transferred
into naïve cells and able to promote M2-like differentiation [55].
Hence, characterization of molecular components of this novel
mechanism of “miR-paracrine signaling” may lead to identiﬁcation
of new targets to regulate macrophage diversity in situ in theatherosclerotic plaque. Irrespectively of the potential use of miRs
as therapeutic targets, another question arises, whether macro-
phage subsets in the plaque could be identiﬁed on the basis of
their miR expression signature. In this regard, the same con-
siderations discussed above (see Section 2) apply. Most of the
evidence on miR expression in macrophage subtypes derives from
in vitro studies under controlled differentiating conditions, but
little is known about the miR signature of plaque macrophages,
whose differentiation programs are modulated by a myriad of
stimuli in the plaque microenvironment. Again, better deﬁnitions
should derive from the growing number of studies aimed at
characterizing the transcriptome of plaque macrophages [19,20]. If
anything, it would not be surprising that, similar to the situation
with canonical markers of M1 and M2 macrophages (see Section 2
above), fully divergent phenotypes in plaques could not be deﬁned
based on absolute presence or absence of a particular set of miRs,
and that relative proportions of speciﬁc miRs would be more in-
formative instead.
It is obvious that we are at the embryonic stage of our under-
standing of the mechanisms of miR-dependent regulation of
macrophage differentiation. Deﬁning which miRs are relevant to
the many macrophage functions in atherosclerosis and narrowing
their targets by systematic in vitro and in vivo validation, will re-
veal potential therapeutic targets and hopefully novel, previously
unforeseen atherorelevant pathways.Acknowledgment
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